Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Context Findings of previous observational studies that examined the association between circulating vitamin D levels and lipid profiles have been inconsistent. Objective A dose-response meta-analysis of epidemiologic studies was conducted to investigate the relationship between serum 25-hydroxyvitamin D levels and dyslipidemia in adults. Data Sources Electronic databases were searched systematically for articles published up to June 2021. Data Extraction Fifty-seven observational studies and 2 cohort studies that reported odds ratios (ORs) or relative risks (RRs) with 95%CIs for dyslipidemia in relation to serum 25-hydroxyvitamin D levels in adults were included. Data Analysis A high level, vs a low level, of serum 25-hydroxyvitamin D was related to a significant 19% decrease in the odds of hypertriglyceridemia (OR 0.81; 95%CI, 0.74–0.89), an 18% reduction in low high-density lipoprotein cholesterol (HDL-C) (OR 0.82; 95%CI, 0.76–0.89), and an 18% reduction in dyslipidemia (OR 0.82; 95%CI, 0.75–0.91). No significant association was found between a high vs a low level of serum 25-hydroxyvitamin D and risk of high low-density lipoprotein cholesterol (LDL-C) levels (OR 0.86; 95%CI, 0.62–1.19) or hypercholesterolemia (OR 1.03; 95%CI, 0.93–1.15). Dose-response analyses demonstrated that each 10 ng/mL increase in the serum 25-hydroxyvitamin D level was linked, respectively, to a 7% (OR 0.93;95%CI, 0.85–1.02), a 3% (OR 0.97; 95%CI, 0.90–1.05), and a 4% (OR 0.96; 95%CI, 0.92–1.00) marginally significant decrease in the odds of hypertriglyceridemia, low HDL-C, and dyslipidemia. Conclusion Higher serum 25-hydroxyvitamin D levels are associated with significant reductions in the odds of hypertriglyceridemia, low HDL-C, and dyslipidemia in a dose-response trend. Systematic Review Registration PROSPERO registration no. CRD42021219484.
Context Findings of previous observational studies that examined the association between circulating vitamin D levels and lipid profiles have been inconsistent. Objective A dose-response meta-analysis of epidemiologic studies was conducted to investigate the relationship between serum 25-hydroxyvitamin D levels and dyslipidemia in adults. Data Sources Electronic databases were searched systematically for articles published up to June 2021. Data Extraction Fifty-seven observational studies and 2 cohort studies that reported odds ratios (ORs) or relative risks (RRs) with 95%CIs for dyslipidemia in relation to serum 25-hydroxyvitamin D levels in adults were included. Data Analysis A high level, vs a low level, of serum 25-hydroxyvitamin D was related to a significant 19% decrease in the odds of hypertriglyceridemia (OR 0.81; 95%CI, 0.74–0.89), an 18% reduction in low high-density lipoprotein cholesterol (HDL-C) (OR 0.82; 95%CI, 0.76–0.89), and an 18% reduction in dyslipidemia (OR 0.82; 95%CI, 0.75–0.91). No significant association was found between a high vs a low level of serum 25-hydroxyvitamin D and risk of high low-density lipoprotein cholesterol (LDL-C) levels (OR 0.86; 95%CI, 0.62–1.19) or hypercholesterolemia (OR 1.03; 95%CI, 0.93–1.15). Dose-response analyses demonstrated that each 10 ng/mL increase in the serum 25-hydroxyvitamin D level was linked, respectively, to a 7% (OR 0.93;95%CI, 0.85–1.02), a 3% (OR 0.97; 95%CI, 0.90–1.05), and a 4% (OR 0.96; 95%CI, 0.92–1.00) marginally significant decrease in the odds of hypertriglyceridemia, low HDL-C, and dyslipidemia. Conclusion Higher serum 25-hydroxyvitamin D levels are associated with significant reductions in the odds of hypertriglyceridemia, low HDL-C, and dyslipidemia in a dose-response trend. Systematic Review Registration PROSPERO registration no. CRD42021219484.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.